EUVIMEDEUVIMED entdecken
Open Access

Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes

Donglan Zhang iD, Nihan Gencerliler, Amrita Mukhopadhyay, Saul Blecker, Morgan E Grams iD, Davene R Wright, Vivian Hsing-Chun Wang iD, Anand Rajan, Eisha Butt, Jung-Im Shin iD, Yunwen Xu iD, Karan R Chhabra und 1 weitere

Diabetes Care · 2025

DOI: 10.2337/dc24-2746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2025. Verfasst von Donglan Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Population Health and Health Services Research, Department of Foundations of Medicine, New York University Grossman Long Island School of …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Cost Sharing, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1RA), and the consequent impact on adverse outcomes, including hospitalizations and emergency department (ED) visits. RESEARCH DESIGN AND METHODS This retrospective cohort study used MarketScan Commercial data (2016–2021). The cohort included nonpregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1RA therapy. Participants were continuously enrolled in the same private insurance plan for 6 months before the prescription date and 1 year thereafter. Exposures included average first 30-day OOP costs for GLP-1RA, categorized into quartiles (lowest [Q1] to highest [Q4]). Primary outcomes were the annual proportion of days covered (PDC) for GLP-1RA and nonadherence, defined as PDC <0.8. Secondary outcomes included diabetes-related and all-cause hospitalizations and ED visits 1 year after GLP-1RA initiation. RESULTS Among 61,907 adults who initiated GLP-1RA, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80–$3,375) had significantly higher odds of nonadherence (odds ratio [OR] 1.25; 95% CI 1.19–1.31) compared with those in Q1 ($0–$21). Nonadherence was linked to increased incidence rates of diabetes-related hospitalizations or ED visits (incidence rate ratio [IRR] 1.86; 95% CI 1.43–2.42), cumulative length of hospitalization (IRR 1.56; 95% CI 1.41–1.72), all-cause ED visits (IRR 1.38; 95% CI 1.32–1.45), and increased ED-related costs ($69.81, 95% CI $53.54–$86.08). CONCLUSIONS Higher OOP costs for GLP-1RA were associated with reduced adherence and increased rates of adverse outcomes among patients with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsCost SharingGlucagon-Like Peptide-1 Receptor AgonistsHumansAdultFemaleMaleMiddle AgedRetrospective StudiesAdolescentYoung AdultHospitalizationEmergency Service, Hospital

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Center for Population Health and Health Services Research, Department of Foundations of Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY.
  • Department of Population Health, New York University Grossman School of Medicine, New York, NY.
  • Leon H. Charney Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY.
  • Department of Surgery, New York University Grossman School of Medicine, New York, NY.
  • Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, MA.
  • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.

ORCID-Profile: Donglan Zhang, Morgan E Grams, Vivian Hsing-Chun Wang, Jung-Im Shin, Yunwen Xu

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIMHD NIH HHS
  • Doucette Innovation Fund

Zitieren

APA

Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H., Rajan, A., Butt, E., Shin, J. I., Xu, Y., Chhabra, K. R., & Divers, J. (2025). Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. Diabetes Care. https://doi.org/10.2337/dc24-2746

Vancouver

Zhang D, Gencerliler N, Mukhopadhyay A, Blecker S, Grams ME, Wright DR, et al. Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. Diabetes Care. 2025. doi:10.2337/dc24-2746

BibTeX
@article{Zhang2025,
  author = {Zhang, Donglan and Gencerliler, Nihan and Mukhopadhyay, Amrita and Blecker, Saul and Grams, Morgan E and Wright, Davene R and Wang, Vivian Hsing-Chun and Rajan, Anand and Butt, Eisha and Shin, Jung-Im and Xu, Yunwen and Chhabra, Karan R and Divers, Jasmin},
  title = {Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc24-2746}
}
Kostenlos starten →